
Evotec, Boehringer Ingelheim, and bioMérieux launch Aurobac
Aurobac Therapeutics SAS goal is to create next-generation antimicrobials and diagnostics to fight Antimicrobial Resistance (AMR). Decades ago, drug...

Urovant Sciences cashes in $75m in licence deal from Pierre Fabre
Swiss Urovant Science, a wholly-owned subsidiary of Sumitovant Biopharma Ltd., will receive up to USD $75m in upfront payment, regulatory, and sales...

Lonza invests CHF500m in Large-Scale Facility in Stein (CH)
Since establishing drug product development and manufacturing services in 2016, Lonza has expanded its clinical drug product offering...

Swedish SOBI awarded rights to market Zynlonta from ADC therapeutics
ADC therapeutics has signed a deal giving Swedish Orphan Biovitrum AB (Sobi) rights to develop and market Zynlonta in hematologic and solid tumor...

G7 heads call for decarbonisation of industry
The G7 ministers underlined the importance of efforts to improve energy efficiency, the need for increased investment in renewable energy, tracking...

Evotec signs contracts with Almirall and Sernova
Under the alliance Evotec is set to discover novel targets or therapeutics for skin diseases such as atopic dermatitis or basal cell carcinoma....

French-German Novasep-PharmaZell Group invests EUR7.3M at Mourenx site
The Novasep-PharmaZell Group has announced a €7.3M investment for its Mourenx site (southwestern France), as part of a larger project supported by...